Menopausal hormone therapy use may be associated with lower cerebral small vessel disease (SVD) burden and greater white matter integrity among cognitively unimpaired older women.
Investigators analyzed data from 352 women in the Gothenburg H70-1944 Birth Cohort in Sweden who underwent brain magnetic resonance imaging (MRI) between 2014 and 2016 at a mean age of 70.8 years, 205 of whom underwent repeat imaging about 5 years later. Reproductive lifespan was defined as the interval between menarche and menopause or bilateral oophorectomy. The investigators also assessed self-reported lifetime use of oral contraceptives (OC) and menopausal hormone therapy (MHT).
The primary imaging measures included cerebral SVD burden and white matter microstructural integrity. The SVD score incorporated white matter hyperintensities, lacunes, cerebral microbleeds, and enlarged perivascular spaces. White matter integrity was assessed using fractional anisotropy derived from diffusion tensor imaging. Additional analyses examined cortical thickness in regions vulnerable to Alzheimer's disease, cerebrospinal fluid biomarkers, APOE–epsilon 4 carrier status, and longitudinal imaging changes. Regression models accounted for education and relevant reproductive or cardiometabolic factors.
Women who had used MHT had 59% lower odds of having at least 2 SVD markers compared with those who had never used MHT. Therapy use was also associated with greater white matter integrity. Both associations remained statistically significant after correction for multiple comparisons.
Each additional year of reproductive lifespan was associated with 8% lower odds of having at least 2 SVD markers. Further analyses suggested that later menopause accounted for this association. However, the reproductive lifespan finding did not remain statistically significant after correction for multiple comparisons.
OC use was associated with greater white matter integrity, although the association did not remain after multiple-comparison correction. In joint exposure analyses, women who reported using both OCs and MHT had 69% lower odds of having at least 2 SVD markers and greater white matter integrity compared with women who had used neither treatment. Both associations remained statistically significant after correction for multiple comparisons. However, the investigators found no statistically significant multiplicative interaction between OCs and MHT.
Analyses of individual vascular markers showed that MHT use was associated with 48% lower odds of cerebral microbleeds and 43% lower odds of enlarged perivascular spaces. Neither association remained statistically significant after correction for multiple comparisons.
Associations with Alzheimer's disease–related neurodegeneration were limited. MHT use was associated with greater cortical thickness in Alzheimer's disease–vulnerable regions among women carrying the APOE–epsilon 4 allele. This association did not remain after correction for multiple comparisons, and no corresponding association was observed among noncarriers. The investigators found no significant overall associations between estrogen exposure and Alzheimer's disease–related cortical thickness or abnormal cerebrospinal fluid biomarkers.
Longitudinal analyses also showed no statistically significant associations between reproductive lifespan or hormonal therapy use and changes in cortical thickness or white matter hyperintensity volume over about 5 years. Although MHT use was associated with a trend toward slower white matter hyperintensity accumulation, the difference was not statistically significant.
The investigators acknowledged several limitations, including the observational design, retrospective self-reported hormonal histories, and limited information on treatment formulation, dose, route, duration, and timing. The small longitudinal imaging sample and potential selection bias from follow-up attrition may have reduced the ability to detect associations over time. Because the cohort consisted of cognitively unimpaired older Swedish women, the findings may not generalize to other populations. The study also could not establish causality or determine whether the observed imaging differences translated into cognitive benefits.
"Our results should be interpreted as contributing to mechanistic understanding rather than immediate clinical translation," wrote lead study author Giulia Lorenzon, of Karolinska Institutet in Sweden, and colleagues.
Full disclosures of the study authors can be found in the study.
Source: Neurology
